Abstract 1830P
Background
Breast cancer (BC) is the most prevalent malignancy in women, both worldwide and at the national level. In addition to classic tumor- and patient-related factors affecting BC prognosis, inflammation, and nutritional status were reported to be significantly associated with carcinogenesis, tumor progression, and cancer prognosis. This study aimed to evaluate the comprehensive prognostic effects of inflammatory and nutritional markers in women with BC and provide a reference for the most relevant prognostic indicators.
Methods
A total of 221 women with stage I-IV BC enrolled in this study between July 2018 and June 2021 were analyzed retrospectively. The pretreatment inflammatory and nutritional markers included C-reactive protein (CRP), albumin, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), pan-immune-inflammation value (PIV), prognostic nutrition index (PNI), and CRP-to-albumin ratio (CAR). The receiving operating curve (ROC) performed the optimal cutoff values. Kaplan-Meier survival analysis, univariate, and multivariate Cox’s proportional hazards regression model were conducted to investigate the effects of the above markers, clinicopathological parameters, and BC treatment on 3-year overall survival (OS).
Results
In ROC, optimal cutoff values for NLR, PLR, LMR, SII, SIRI, PIV, PNI, and CAR were determined as >1.99, >146, <3.65, >207, >1.305, >542.5, <50.9, and >1.34, respectively. The tumor (T), lymph node (N), metastases (M) stage, molecular subtype, surgery status (mastectomy vs non-mastectomy), NLR, SII, SIRI, PIV, and CAR were significantly associated with 3-year OS in univariate analysis. Further, multivariate analysis showed that patients with T3-4, N1-3, HER2-enriched subtype, NLR>1.99 (HR 2.58, 95%CI 1.04–6.36, p=0.040), and CAR>1.34 (HR 3.15, 95% CI 1.56–6.33, p=0.001) were significantly associated with worse prognosis.
Conclusions
Besides the classical survival factors such as T, N, and molecular subtypes, NLR and CAR were significantly associated with the 3-year OS and may serve as prognostic indicators of BC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The Indonesian Ministry of Research, Technology, and Higher Education.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1950P - Squamous cell carcinoma of unknown primary (SCCUP): A genomic landscape study
Presenter: Hannah Robinson
Session: Poster session 12
1951P - A multicenter, retrospective study of non-small-cell lung carcinoma (NSCLC) harboring EGFR exon 20 insertions: Distribution, variants, and prevalence of coalterations
Presenter: Ivana Gabriela Sullivan
Session: Poster session 12
1952P - Multiomic spatial profiling of whole-slide NSCLC tissues from patients receiving anti PD-1 therapy identifies metabolic phenotypes associated with therapy resistance
Presenter: Arutha Kulasinghe
Session: Poster session 12
1953P - The ATXN3-USP25-TRMT1 axis regulates tRNAm2,2G modification and promotes osimertinib resistance in lung cancer
Presenter: Tianqing Chu
Session: Poster session 12
Resources:
Abstract